Replies to post #2177849 on STOCK GOODIES PLAYS OF THE WEEK

[1jk1]

$GCEI ON HIGH ALERT>LOAD UP ON THE CHEAPIES.


* Please Read Important information> (below)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120928532


Latest news @ http://www.otcmarkets.com/stock/GCEI/news



$GCEI IS UNDER THE RADAR.


Go GREEN with Global Clean Energy a Enviromentally Friendly Waste 2 Fuel & PGM (Platinum-Group-Metals) Auto Catalysts Recovery Company

http://www.globalcleanenergy.net/

glta

[1jk1]

$GCEI ON HIGH ALERT>($329bn) Global clean energy investment attracted a record $329bn last year, according to Bloomberg New Energy Finance


http://www.theguardian.com/environment/2016/jan/27/un-urges-business-leaders-to-double-investment-in-green-energy-by-2020


Stock Price Extremely Undervalued.



Go GREEN with Global Clean Energy a Enviromentally Friendly Waste 2 Fuel & PGM (Platinum-Group-Metals) Auto Catalysts Recovery Company




Visit> http://www.globalcleanenergy.net


glta

[marirstk]

$EGT Weekly Bullish Chart
---------------------------------------





$EGT Daily Chart
-----------------------




$EGT Long Term Weekly Chart
---------------------------------------




$EGT Weekly Chart
-----------------------------



$EGT Chart - Finviz
-----------------------------

[mick]

hi my friend/ good evening/ WWIO could be big one /////\\\\\

first play in couple mos.

[1jk1]

$GCEI ALERT> Earl Azimov/CEO: Azimov was a cousin of the late science fiction great Isaac Asimov.
Read more at

http://www.itftennis.com/news/176793.aspx#kg1k3ut5LpHxQxEP.99


A walk on the BallenIsles grounds early in the day found Dr. Earl Azimov, an optometrist from Montreal, Canada, who also owns the cutting edge Global Clean Energy company, watching his good friend Ernie Fink play. Fink, also from Montreal but a well-known teaching pro in the Orlando, Fla. area, was playing his Men’s 50 first-round match against American Rill Baxter.

As it turned out, Azimov lost in the qualifying rounds the day before, but will play doubles with Fink. Azimov, however, wasn’t at all upset about his loss to Carlos Garcia in the third round of qualifying, even admitting: “He slaughtered me. It was too hot for my Canadian blood.”

But there was another reason that Azimov was happy to just be playing in the Seniors World Championships. The last time he played the event was when it was in Mallorca, Spain five years ago. While he was in Mallorca he said he kept complaining his stomach hurt.

When he went home it was discovered he had non-Hodgkins Lymphoma. During his battle against cancer his mother, a Holocaust survivor, offered him these inspirational words of wisdom: “If I can survive Auschwitz you can survive cancer.” And she was right.

So for Azimov, who played college tennis for Coastal Carolina in the 80s, being back at the World Championships is already a major victory. As he puts it: “Every day is a good day, win or lose. If you’re breathing it’s a good day.”

And yes, in case you’re wondering, Azimov was a cousin of the late science fiction great Isaac Asimov.

Read more at http://www.itftennis.com/news/176793.aspx#kg1k3ut5LpHxQxEP.99








$GCEI> STRONG UPTREND:

http://club.ino.com/trend/analysis/stock/GCEI/?mkt=toppennyemail-symbols&id=2BA0C3&ticket=7b89abbf8cg06a08a08806608c06c


READ the ANNUAL REPORT just filed. (pages 5-7)


http://www.barchart.com/quotes/stocks/GCEI STRONG BUY



STOCK IS EXTREMELY UNDERVALUED IMHO!



Go GREEN with Global Clean Energy a Enviromentally Friendly Waste 2 Fuel & PGM (Platinum-Group-Metals) Auto Catalysts Recovery Company.

http://www.globalcleanenergy.net/


glta

[$Pistol Pete$]

$PMCB PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture

Source: GlobeNewswire Inc.

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte’s biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte’s pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.
Dr. Steven Chamow of Chamow & Associates stated, “Use of the live-cell encapsulation technology is very complex with many manufacturing steps and processes. GMP readiness of a biologic manufacturing facility such as the Bangkok site is no exception. In a relatively short period of time, with the relentless and determined cooperation we received from Austrianova, the facility is ready for GMP manufacture to produce the encapsulated cells that are a major part of PharmaCyte’s pancreatic cancer therapy.”

PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are delighted to announce this exciting milestone in the development of our therapy for pancreatic cancer. This is a major step in generating the overall Chemistry, Manufacturing and Controls (CMC) information, which makes up a large part of the pre-IND package we will be submitting to the U.S. Food and Drug Administration (FDA). We would like to thank Chamow & Associates and Austrianova for completing this process. With the facility ready for cGMP manufacture, we are now in a position to engage with the FDA to discuss our clinical investigational plan and initiate our first clinical trial.”

Over the last few months, following an initial on-site audit of the facility by Chamow & Associates, numerous detailed documents were required to be prepared, reviewed and approved by Chamow. These documents include the quality management system manual and a variety of facility-related standard operating procedures (SOPs). In addition, all facility-related equipment has successfully completed the necessary Installation Qualifications (IQ) and Operational Qualifications (OQ).

Dr. Brian Salmons, the Chief Executive Officer of Austrianova, said, “We are exceedingly pleased that we were able to have our unique state-of-the-art live-cell encapsulation facility assessed as ready for GMP manufacture by Chamow & Associates. Both of the teams from Austrianova and Chamow worked together seamlessly and virtually nonstop to ensure that the facility is ready for GMP manufacture of PharmaCyte’s biologic product. We did so to enable PharmaCyte to reach the clinic with its novel therapy for pancreatic cancer at the earliest opportunity.”

The Austrianova facility will be used to encapsulate the genetically engineered live human cells that, together with low doses of the cancer prodrug ifosfamide, make up PharmaCyte’s pancreatic cancer therapy. PharmaCyte’s cancer therapy attacks the pancreas tumor with “targeted chemotherapy,” resulting in significant tumor shrinkage, the ability to convert some tumors from inoperable to operable, a reduction in the pain associated with the disease and an improvement to a patient’s overall quality of life.

PharmaCyte’s upcoming clinical trial in advanced inoperable pancreatic cancer involves placing the genetically modified live cells near the blood supply to the pancreas. The cancer prodrug ifosfamide is then given at one-third the normal dose. The prodrug is converted to its active form at the site of the tumor. In an earlier Phase 1/2 clinical trial, this “targeted chemotherapy” demonstrated far greater efficacy than the then “gold-standard” of care with no meaningful side-effects from the chemotherapy. Patients enrolled in PharmaCyte’s clinical trial will have non-metastatic, locally advanced and inoperable pancreatic cancer. They will be eligible for the trial if their tumors are either stable or progressing after 4-6 cycles of treatment with either of the two most commonly used chemotherapies for these cancers - the two-drug combination of Abraxane® plus gemcitabine or the four-drug combination known as FOLFIRINOX. PharmaCyte’s therapy will be compared in such patients with the current “standard of care,” which consists of the combination of the anticancer drug capecitabine plus radiation.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. The encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated live cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]


Primary Logo

[$Pistol Pete$]

$PMCB PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture



SILVER SPRING, Md., April 25, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte’s biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte’s pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.

Dr. Steven Chamow of Chamow & Associates stated, “Use of the live-cell encapsulation technology is very complex with many manufacturing steps and processes. GMP readiness of a biologic manufacturing facility such as the Bangkok site is no exception. In a relatively short period of time, with the relentless and determined cooperation we received from Austrianova, the facility is ready for GMP manufacture to produce the encapsulated cells that are a major part of PharmaCyte’s pancreatic cancer therapy.”

PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are delighted to announce this exciting milestone in the development of our therapy for pancreatic cancer. This is a major step in generating the overall Chemistry, Manufacturing and Controls (CMC) information, which makes up a large part of the pre-IND package we will be submitting to the U.S. Food and Drug Administration (FDA). We would like to thank Chamow & Associates and Austrianova for completing this process. With the facility ready for cGMP manufacture, we are now in a position to engage with the FDA to discuss our clinical investigational plan and initiate our first clinical trial.”

Over the last few months, following an initial on-site audit of the facility by Chamow & Associates, numerous detailed documents were required to be prepared, reviewed and approved by Chamow. These documents include the quality management system manual and a variety of facility-related standard operating procedures (SOPs). In addition, all facility-related equipment has successfully completed the necessary Installation Qualifications (IQ) and Operational Qualifications (OQ).

Dr. Brian Salmons, the Chief Executive Officer of Austrianova, said, “We are exceedingly pleased that we were able to have our unique state-of-the-art live-cell encapsulation facility assessed as ready for GMP manufacture by Chamow & Associates. Both of the teams from Austrianova and Chamow worked together seamlessly and virtually nonstop to ensure that the facility is ready for GMP manufacture of PharmaCyte’s biologic product. We did so to enable PharmaCyte to reach the clinic with its novel therapy for pancreatic cancer at the earliest opportunity.”

The Austrianova facility will be used to encapsulate the genetically engineered live human cells that, together with low doses of the cancer prodrug ifosfamide, make up PharmaCyte’s pancreatic cancer therapy. PharmaCyte’s cancer therapy attacks the pancreas tumor with “targeted chemotherapy,” resulting in significant tumor shrinkage, the ability to convert some tumors from inoperable to operable, a reduction in the pain associated with the disease and an improvement to a patient’s overall quality of life.

PharmaCyte’s upcoming clinical trial in advanced inoperable pancreatic cancer involves placing the genetically modified live cells near the blood supply to the pancreas. The cancer prodrug ifosfamide is then given at one-third the normal dose. The prodrug is converted to its active form at the site of the tumor. In an earlier Phase 1/2 clinical trial, this “targeted chemotherapy” demonstrated far greater efficacy than the then “gold-standard” of care with no meaningful side-effects from the chemotherapy. Patients enrolled in PharmaCyte’s clinical trial will have non-metastatic, locally advanced and inoperable pancreatic cancer. They will be eligible for the trial if their tumors are either stable or progressing after 4-6 cycles of treatment with either of the two most commonly used chemotherapies for these cancers – the two-drug combination of Abraxane® plus gemcitabine or the four-drug combination known as FOLFIRINOX. PharmaCyte’s therapy will be compared in such patients with the current “standard of care,” which consists of the combination of the anticancer drug capecitabine plus radiation.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. The encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated live cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte and its future events and results that involve inherent risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]

http://investingnews.com/daily/life-science-investing/biotech-investing/pharmacyte-biotechs-live-cell-encapsulation-facility-commissioned-gmp-manufacture/

[mick]

good morning/ from 1's, BSSP 0.0003 +0.0001 +50.00% 216,388,452 Reve Technologies, Inc.

[AugustaFriends]

$XCO volume pouring in Target $2.75+++

[AugustaFriends]

$HUSA up 50% was a $14 stock break .35 Kaboom $HUSA http://schrts.co/ykdZQ2

[BottomBounce]

$GEVO Breakout MODE

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor



SILVER SPRING, Md., May 03, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.

Dr. Sanjay Batra brings to PharmaCyte more than 20 years of global healthcare and entrepreneurial experience in start-ups, biotech and large pharma. Dr. Batra spent 10 years at Johnson & Johnson, culminating as Vice President, R&D Pharmaceuticals, Asia-Pacific and Japan. He is highly skilled in partnering with diverse stakeholders, such pharmaceutical companies, the investment community, academia and key opinion leaders. In addition, Dr. Batra has been involved in over 80 clinical trials in all phases of development and commercialization.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of Dr. Batra’s appointment, “We are pleased that Dr. Batra has agreed to join our team, as we now have a cGMP-compliant facility and are ready to enter into the next phase of our life-cycle as a biotech company. We believe that his experience at Johnson & Johnson and his global network will prove invaluable to PharmaCyte. His expertise in scientific, medical and business areas, both domestically and internationally, will be a key asset as we move PharmaCyte forward towards the successful development of our novel platform technology to treat pancreatic cancer and diabetes.”

Dr. Batra said, “I am very excited to be part of the PharmaCyte team at this pivotal time. The technology holds tremendous promise to help physicians and their patients in areas of significant unmet medical need. Mr. Waggoner has built a very solid organization, and I look forward to making contributions with pace and rigor to advance our product pipeline towards commercialization.”

Most recently, Dr. Batra served as President and CEO of Aesthetic Factors, an emerging company providing autologous, point-of-care therapies in Regenerative Medicine. In this role, Dr. Batra led the commercial growth of their platelet-rich plasma and autologous fat products and was instrumental in establishing the company as the science driven leader. In 2013, Dr. Batra founded VIAS Partners with the aspiration to take his diverse experiences and global network to partner with entrepreneurs and companies to advance their business concepts.

Dr. Batra obtained his Ph.D. in medical physiology from the University of Ottawa, Canada, and completed his post-doctoral training with world-renowned scientists in Japan and Switzerland. He is a Fellow of the American College of Cardiology and an Adjunct Professor at the Wake Forest Institute for Regenerative Medicine. Dr. Batra has published over 50 papers and 70 abstracts, and has made more than 100 invited scientific presentations.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]

[mick]

good morning, all good health ?????

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor



SILVER SPRING, Md., May 03, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.

Dr. Sanjay Batra brings to PharmaCyte more than 20 years of global healthcare and entrepreneurial experience in start-ups, biotech and large pharma. Dr. Batra spent 10 years at Johnson & Johnson, culminating as Vice President, R&D Pharmaceuticals, Asia-Pacific and Japan. He is highly skilled in partnering with diverse stakeholders, such pharmaceutical companies, the investment community, academia and key opinion leaders. In addition, Dr. Batra has been involved in over 80 clinical trials in all phases of development and commercialization.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of Dr. Batra’s appointment, “We are pleased that Dr. Batra has agreed to join our team, as we now have a cGMP-compliant facility and are ready to enter into the next phase of our life-cycle as a biotech company. We believe that his experience at Johnson & Johnson and his global network will prove invaluable to PharmaCyte. His expertise in scientific, medical and business areas, both domestically and internationally, will be a key asset as we move PharmaCyte forward towards the successful development of our novel platform technology to treat pancreatic cancer and diabetes.”

Dr. Batra said, “I am very excited to be part of the PharmaCyte team at this pivotal time. The technology holds tremendous promise to help physicians and their patients in areas of significant unmet medical need. Mr. Waggoner has built a very solid organization, and I look forward to making contributions with pace and rigor to advance our product pipeline towards commercialization.”

Most recently, Dr. Batra served as President and CEO of Aesthetic Factors, an emerging company providing autologous, point-of-care therapies in Regenerative Medicine. In this role, Dr. Batra led the commercial growth of their platelet-rich plasma and autologous fat products and was instrumental in establishing the company as the science driven leader. In 2013, Dr. Batra founded VIAS Partners with the aspiration to take his diverse experiences and global network to partner with entrepreneurs and companies to advance their business concepts.

Dr. Batra obtained his Ph.D. in medical physiology from the University of Ottawa, Canada, and completed his post-doctoral training with world-renowned scientists in Japan and Switzerland. He is a Fellow of the American College of Cardiology and an Adjunct Professor at the Wake Forest Institute for Regenerative Medicine. Dr. Batra has published over 50 papers and 70 abstracts, and has made more than 100 invited scientific presentations.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]

[BottomBounce]

$HEMP Hemp, Inc.'s Processing Facility Proudly Offers Its First Product for Sale http://beforeitsnews.com/financial-markets/2016/05/hemp-news-hemp-inc-s-processing-facility-proudly-offers-its-first-product-for-sale-hemp-2869143.html

[BottomBounce]

Ladenburg Thalmann maintains Buy on $CUBA raises target to $8.25

[mick]

good morning, just back from ak-chin. nice trip

[BottomBounce]

*** $CUBA up she goes

[BottomBounce]

On this news - I put mine out to .008, may get greedy and change to .01+, "ERBB News: American Green Buys Premium Dispensary Property in Tempe, Arizona"

[BottomBounce]

$AMRS Working with DARPA - U.S. Department of Defense Advanced Research Projects Agency (DARPA), Amyris is encoding DNA to create high performance materials to meet the needs of a growing world. These advanced technologies developed under the DARPA Living Foundries program are leading the synthetic biology industrial revolution that drives a 350 billion dollar bioeconomy. https://amyris.com/collaborations/darpa/

[BottomBounce]

Tweet on $LEXG Lithium Mining @ http://Twitter.com/MiningInfo

[BottomBounce]

$AMRS Biotech Breaking out ! .596 + 0.0057

[BottomBounce]

MJ NEWS!!! $ERBB Zoned Properties Chosen to Build American Green's 15,000 Sq. Ft. Cultivation Facility in Parachute, CO http://finance.yahoo.com/news/zoned-properties-chosen-build-american-120000476.html

[1jk1]

$GCEI HUGE NEWS> Global Clean Energy on Track to Close PGM Acquisition by early June 2016 (For Newbies)

http://www.altenergymag.com/news/2016/05/02/global-clean-energy-on-tract-to-close-pgm-acquisition-by-early-june-2016---first-quarter-update-/23523/


Automotive Catalytic Converter/$272.95bn Market Size Is Expected To Reach USD 272.95 Billion By 2024: Grand View Research, Inc. (below)


http://www.pressreleaserocket.net/automotive-catalytic-converter-market-size-is-expected-to-reach-usd-272-95-billion-by-2024-grand-view-research-inc/444757/





STOCK IS EXTREMELY UNDERVALUED IMHO!



Go GREEN with Global Clean Energy a Enviromentally Friendly Waste 2 Fuel & PGM (Platinum-Group-Metals) Auto Catalysts Recovery Company.

http://www.globalcleanenergy.net/


glta

[BottomBounce]

$AMRS .59 +0.04 (8.18%)

[Murdoc]

$ULGX 35M AS shell @.003 seeing accumulation and higher lows. Watch this one could turn into a huge gainer quick. Chart shaping up looking bullish for a push

[mick]

how ya do'ins my friend ?????

[$Pistol Pete$]

$PMCB Could this mark the end of insulin injections for type 1 diabetics? Cells genetically modified to produce insulin 'could transform life for millions'

* Genetically modified cells could replace need for daily insulin injections

* The cell line is engineered to produce, store and release insulin in response to blood sugar levels in the human body

*Transplantation of cells into type 1 diabetics could signal first cure

Genetically modified cells could eliminate the need for daily injections to treat type 1 diabetes, experts have revealed.
The human cell line is genetically engineered to produce, store and release insulin in response to blood sugar levels in the human body.
Scientists said the insulin-producing 'Melligen' cells show promise as a possible cure for type 1 diabetes.
In type 1 diabetes, the immune system destroys the pancreatic cells responsible for making insulin, a hormone crucial to converting blood sugar into energy.
This month, they secured US patent protection for the cell line from the US Patent and Trademark Office.



Professor Ann Simpson, who led the team at the University of Technology, Sydney, said: 'My team and I are extremely pleased that the US patent for the Melligen cells has been granted.
'This takes us a step closer to releasing diabetics from the need to inject insulin daily, and more importantly, protecting them from the debilitating complications of the disease, such as blindness, kidney failure and cardiovascular problems.'

The researchers are now working with US clinical biotech firm PharmaCyte Biotech to develop the research into new treatments.

PharmaCyte specialises in the development of targeted treatments for cancer and diabetes using its signature live cell encapsulation technology.

This technology, known as Cell-in-a-Box, is a key process in the commercialisation of the Melligen cell as a revolutionary treatment.

'This is a culmination of many years' work by our group and we look forward to working with PharmaCyte's Diabetes Consortium to utilise the Cell-in–a-Box technology to encapsulate the cells for preclinical trials aimed at curing diabetes,' said Professor Simpson.
'We anticipate that the capsule technology will protect the Melligen cells from the body's immune response that normally destroys foreign tissue, allowing the Melligen cells to be transplanted into humans.'



PharmaCyte's chief executive officer, Kenneth Waggoner, said: 'We at PharmaCyte consider ourselves to be very fortunate in having secured the exclusive world-wide licence to use the Melligen cells to develop a treatment for diabetes.
'If we are successful in this effort, it will bring to fruition the many years of research that have been conducted by Professor Simpson and her colleagues at UTS in developing these remarkable cells.
'Importantly, we are very pleased that Professor Simpson will be assisting PharmaCyte in this endeavour as a member of our International Diabetes Consortium.
'For the millions of people worldwide who suffer from a disease of epidemic proportions, our treatment could relieve them of the onerous daily requirements for insulin administration and dietary restrictions and offer a life free from the very serious and even life-threatening complications associated with diabetes.'
With the World Health Organization attributing more than 1.5 million deaths to diabetes in 2012 and more than 422 million adults suffering from the disease in 2014, the development has the potential to impact millions of lives.
The cell line already has patent protection from the European counterpart to the US Patent and Trademark Office and the patent has been validated in France, Switzerland, Great Britain, Ireland, Germany, Spain, Denmark, Italy and the Netherlands.

Read more: http://www.dailymail.co.uk/health/article-3605238/Could-mark-end-insulin-injections-type-1-diabetics-Cells-genetically-modified-produce-insulin-transform-life-millions.html#ixzz49Ws14wst
Follow us: @MailOnline on Twitter | DailyMail on Facebook

[ZipCash]

$NNRX OnFire $$$ 10,000 healthcare clinics which will soon carry NutraNomics' Amazon Protocol line of products under its One Care brand.

[BottomBounce]

COVER:):):) $AMRS .5502 +0.043 (8.48%)

[mick]

good morning.

[mick]

Memorial Day always, Memorial Day Weekend /////\\\\\ all have great one.

friend are what it is all about.

we pray for all military and their families and those departed for keeping america free and safe.

[mick]

happy sunday, long wkend thing , we pray for oue military, past presnet and future.

[mick]

good morning, nice day in da parks

[mick]

ribs steak hot dogs hamburgers --- salads --- fries --- beer --- soda

have ah good one

[mick]

good morning, one hitter today/ OPTT up smartly

[mick]

good morning/ vuzi

http://www.barchart.com/cheatsheet.php?sym=vuzi

[mick]

#1 WWIO/ excerpt/to showcase includes, cutting-edge startups/05-25-2016/ SHANGHAI--(BUSINESS WIRE)--

from partners including Akyumen

thank you, very good reading. 05-25-2016/ SHANGHAI--(BUSINESS WIRE)--


Morning... some WWIO GidDy uP DD...

YES released 2 days ago...

May 25, 2016 3:00 AM

GSMA Innovation City Returns to Mobile World Congress Shanghai 2016

Immersive Exhibition Demonstrates How Mobile Technology is
Transforming Our Lives;
Partners Include Akyumen,
DTS,
Hangar 18 NOA,
Huawei,
KT Corporation,
MyFC,
NAES,
nubia,
OPPO and
Thinfilm

Business Wire GSMA
May 25, 2016 3:00 AM

?????

Thank you for helping us improve your Yahoo experience
Learn more about your feedback.

SHANGHAI--(BUSINESS WIRE)--

The GSMA Innovation City will return to Mobile World Congress
Shanghai 2016 for the fourth year running, the GSMA announced today.

The popular exhibition space will again be a focal point of the s
how and invites visitors to explore an immersive environment that demonstrates how intelligent mobile-connected products and services
are positively changing the world around us.

This year’s showcase includes a diverse range of experiences
from cutting-edge startups as well as more established companies,
and covers sectors such as
retail,
transport,
automotive,
sport and more.

“The City continues to be one of the most popular attractions at
Mobile World Congress and is the perfect place to experience the
latest trends and innovations in mobile all at one destination.
This year we have expanded the City to include dedicated zones
covering particular interest areas such as automotive,
home, retail and sport.

It really does have something that caters to every interest in
mobile and we look forward to welcoming visitors to this
year’s show,” said Michael O’Hara, Chief Marketing Officer, GSMA.

The GSMA Innovation City will include interactive demonstrations
from
partners including Akyumen,
DTS, Hangar 18 NOA,
Huawei,
KT Corporation,
MyFC,
NAES,
nubia,
OPPO and
Thinfilm, as well as from the GSMA’s key industry programmes
Connected Living, Digital Commerce, Network 2020 and Personal Data.

This year the City includes a number of dedicated ‘Connected Zones’
that focus on particular interest areas such as sports, automotive, retail and innovation,
as well as the OPPO café and the GSMA Pavilion.

Showcasing a Range of New Experiences

GSMA partner experiences on display in the Innovation City include:

AKYUMEN

Akyumen will showcase its new Holofone Hawk 5.5" Projector Smartphone that can project videos,
pictures, presentations and mobile apps onto a large screen.
It will also demonstrate its Holofone Phablet and Falcon Tablet that features built-in state of the art proprietary Projector technology running on Windows 10 OS.
Akyumen's Chairman and CEO, Aasim Saied, will also unveil the Akyumen TV Mobile Entertainment Platform.


http://finance.yahoo.com/news/gsma-innovation-city-returns-mobile-070000002.html

[mick]

#1/Changes in Caveat Emptor Status

http://emerginggrowth.com/caveat-emptor-status-changes/


05/16/2016 APHD Appiphany Technologies Holdings Corp. OTC Pink Current Added Common Stock
05/11/2016 TERX Terra Inventions Corp. Grey Market Added Common Stock
05/11/2016 PHUN PetroHunter Energy Corp. Grey Market Added Common Stock
05/11/2016 NTLNF Northcore Technologies Inc. Grey Market Added Ordinary Shares
05/11/2016 LUVE Luve Sports Inc. Grey Market Added Common Stock
05/11/2016 INKN Shrink Nanotechnologies, Inc. Grey Market Added Common Stock
05/11/2016 GROV GroveWare Technologies Ltd. Grey Market Added Common Stock
05/06/2016 CPCCD Striper Energy, Inc. Grey Market Added Common Stock
05/04/2016 REXEF Rush Exploration, Inc. Grey Market Added Ordinary Shares
05/04/2016 LBGO Liberty Gold Corp. Grey Market Added Common Stock
05/04/2016 HMNC Hondo Minerals Corporation Grey Market Added Common Stock
05/04/2016 GIREF Giant Resources, Inc. Grey Market Added Ordinary Shares
05/04/2016 CLNO EQCO2, Inc. Grey Market Added Common Stock
05/03/2016 SLRW Solarbrook Water & Power Corp. Grey Market Added Common Stock
05/03/2016 KALY Kali, Inc. OTC Pink Current Removed Common Stock
04/29/2016 SHDH Shades Holdings, Inc. Grey Market Added Common Stock
04/29/2016 PRVT Private Media Group, Inc. Grey Market Added Common Stock
04/29/2016 PIEX Pioneer Exploration, Inc. Grey Market Added Common Stock
04/29/2016 MMAM Medical Makeover Corporation of America Grey Market Added Common Stock
04/29/2016 HIDC Harbor Island Development Corp Grey Market Added Common Stock
04/29/2016 EZRTD West Coast Ventures Group Corp. OTC Pink Current Removed Common Stock
04/29/2016 COYR Coyote Resources, Inc. Grey Market Added Common Stock
04/29/2016 CLOW Cloudweb, Inc. OTC Pink Current Removed Common Stock
04/29/2016 BRND Premier Brands, Inc. Grey Market Added Common Stock
04/29/2016 XFLS Xfuels Inc. OTC Pink No Information Added Common Stock
04/27/2016 MWOG Midwest Oil and Gas, Inc. Grey Market Added Common Stock
04/27/2016 EURI AgriEuro Corp. OTC Pink Current Removed Common Stock
04/26/2016 VLBI Valentine Beauty, Inc. Grey Market Added Common Stock
04/22/2016 NERG NuTech Energy Resources, Inc. OTC Pink Current Removed Common Stock
04/21/2016 MSSD Massive Dynamics, Inc. Grey Market Added Common Stock
04/21/2016 MFTH Medisafe 1 Technologies Corp. Grey Market Added Common Stock
04/21/2016 MDTV MDU Communications International, Inc. Grey Market Added Common Stock
04/21/2016 GLHV Global Health Voyager, Inc. Grey Market Added Common Stock
04/21/2016 GHML Gold Hills Mining, Ltd. Grey Market Added Common Stock
04/21/2016 DTVI Dot VN, Inc. Grey Market Added Common Stock
04/12/2016 ITNS ITonis, Inc. OTC Pink Current Added Common Stock
04/11/2016 WOTC W3OTC, Inc. Grey Market Added Common Stock
04/11/2016 VSDL Versadial, Inc. Grey Market Added Common Stock
04/11/2016 VOXR Voxcorp, Inc. Grey Market Added Common Stock
04/11/2016 USWL US-Worldlink.com, Inc. Grey Market Added Common Stock
04/11/2016 TDNC Tradings.net, Inc. Grey Market Added Common Stock
04/11/2016 SNMBQ Sona Mobile Holdings Corp Grey Market Added Common Stock
04/11/2016 SNDH Standard Holdings Group, Ltd. Grey Market Added Common Stock
04/11/2016 SAOA Seaboard Associates, Inc. Grey Market Added Common Stock
04/11/2016 PRNI Printron, Inc. Grey Market Added Common Stock
04/11/2016 PNAR Pan American Resources, Inc. Grey Market Added Common Stock
04/11/2016 MNET Multicom Publishing Grey Market Added Common Stock
04/11/2016 JPCB J.P. Cabot Realty, Inc. Grey Market Added Common Stock
04/11/2016 ITSW International Total Services, Inc. Grey Market Added Common Stock
04/11/2016 HIRD Diversified Corporate Resources, Inc. Grey Market Added Common Stock

[mick]

could be huge/ huge reporting/ $IDGC news out / idgc/ ID Global Corporation Records Profitable 2015 and Posts Q4

ID Global Corporation Records Profitable 2015 and Posts Q4 and Annual Report

Source: InvestorsHub NewsWire

ID Global Corporation Records Profitable 2015 and Posts Q4 and
Annual Report

Bannockburn, IL -- June 3, 2016 -- InvestorsHub NewsWire
-- ID Global Corp. (OTC: IDGC) is pleased to announce that it has completed and
released its 4th Quarter-end and Annual Report for 2015 and finished a profitable year.
The company has also amended and reduced the conversion privileges
of the Series A Convertible Preferred Shares into common shares
from 10 billion to 100 million common shares, while maintaining
its voting privileges.

As a result, the number of shares outstanding calculated on a fully-diluted basis is decreased by 9.9 billion common shares.

The financial statement is available on our website http://www.idglobal-corp.com

Sebastien DuFort, president and CEO stated "The company and our strategic partners have been very diligent in seeking out revenue producing projects while management operated very lean and worked
hard on reducing debt.

The Company will have a full corporate update in the very near future

About ID Global Corporation

ID Global Corporation (IDGC) is a diversified holdings company with a focus on emerging and
middle market investment opportunities in North America. I

DGC seeks, through debt and equity investments,
minority positions as well controlling interests in
established companies and special situation start-ups.

Forward-Looking Statements

This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of ID Global Corporation and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Sebastien C. DuFort

http://www.idglobal-corp.com

[mick]

i like bread and butter bread peanut butter and jam

[mick]

good afternoon.

[mick]

riding on cloud nine if were any clouds here in yuma,az so settle for bags of sand

[BottomBounce]

$$$$$$ NEWS!!!! $AMRS .5945 + 0.073 (14.00%) $$$$$$

[mick]

howdy , my friend/ 06-14-2016 our flag day june 14

[BottomBounce]

$AMRS Bull Run .535 +0.0175 (3.38%)

[mick]

good morning/ good morning all on 'STOCKGOODIES PLAYS OF THE WEEK '

[mick]

notice narrow range since btm'd in jan.,2016 PMCB



[-chart]www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=PMCB&size=analysis&support=0.05,2,0.06,2,0.06,18,0.06,2,0.07,4,0.07,14,0.07,2,0.07,2,0.08,2,0.08,2,0.08,2&trend=[/chart]

http://www.stockta.com/cgi-bin/analysis.pl?symb=PMCB&cobrand=&mode=stock

[mick]

had some car problems yesterday/ A/C wasn't working.

[mick]

READY FOR LONG WKEND ?????

[mick]

good evening, i had some challenges last couple days.

[Hedgebunny]

TGD is going up, THAT SUX!!! LMAOLOL>>>>>

[Hedgebunny]

BCND is a good one too short!!! lmao lol....

Go down their and short it, i just saw it at .0004 not too long ago! lmao lol......

[mick]

ORRP is at the right place at the right time with lithium seeing explosive growth with little sign of slowing down. Prices for Lithium carbonate are up 47% from the average price in 2015 in the first quarter of this year and numerous sources have reported the potential growth in demand for Lithium to be very robust. In a report from Goldman Sachs called “What if I told you” Goldman refers to lithium as the “new gasoline”. This is due to increasing demand for EV’s. The cause is that the lithium market could triple from the current demand of 160,000mt to 470,000mt by 2025.

ORRP recently made a big move when they acquired the Western Nevada Basin project (“WNB”), in Southwest Nevada. The WNB Project covers the central portion of an area first identified as lithium rich by the United States Geological Survey. The WNB Project includes 500 mining claims covering approximately 10,000 acres. The Company also has an exclusive option to acquire an additional 600 mining claims for a total of 22,000 acres.

[AugustaFriends]

$NEOT 1.10 BREAKOUT!!!! alert

[mick]

it is thursday, 07-28-2016 , good morning.

[AugustaFriends]

$THM 1.10 watch for HUGE BUY at 1.11 trigger $THM http://schrts.co/IuOMr2

[mick]

good morning my friend.

[Ecomike]

$OPXS rallied about 38% today on a 10-Q filing that showed their first quarterly profit since they went public in 2009. US Defense contractor selling for 1/3 of book value. Over 20 million in annual revenue. Float is 200,000 shares, OS under 1.7 million shares, OTC stock that is bound for NASDAQ

[BottomBounce]

$KNDI Golden Cross

[mick]

good morning, monsoon hitting tucson phoenix heavy.

[136]

$AMMJ Uptrend starting

Financial report could be out as early as Friday!

Company is expected to be NET PROFITABLE.

Not one to miss out on IMO

Tweet?

GLTY!

[mick]

how ya doing this friday morn ?????

[mick]

good morning, 08-13-2016

[mick]

happy friday ????? T.G.I.F. 08-19-2016

[mick]

RMHB/ Rocky Mountain High Brands, Inc.
ah Dallas-based consumer goods brand development company.
The Company specializes in the development, manufacture, marketing,
and distribution of high quality, health conscious,
hemp-infused food and beverage products. For more information visit: http://rockymountainhighbrands.com



https://youtu.be/gsIhOC7VV_0

" rel="nofollow" target="_blank">https://youtu.be/

[BottomBounce]

$AMRS Amyris - A Juggernaut In The Making
http://seekingalpha.com/article/3999958-amyris-juggernaut-making

[mick]

THOSE EYES HAVE IT, GOOD MORNING.

[mick]

good morning/ finally getting settle in new home ?????

[vikingzskillz]

HUGE @EpglMed $EPGL has patented the use of the fluid medium in a lens case to transmit data and power. All future smart lenses will likely need the use of a fluid medium. $EPGL patents the enhancement of the signal via the fluid, all in one reusable case.

[mick]

HOW IS YOUR WKEND ?????

[mick]

got passed hump day, now ready fer long long long weekend, i did lot of labor

[mick]

world trade , still big target in u.s.a.

[mick]

ground zero in da rising ,

[Ecomike]

$MVTG rallied 18% today on 1/2 million shares, huge volume spike all bought at the ask, a large premium, and we are days to weeks away from news about the mega million dollar pilot plant funding grant in Europe, Horizon 2020 grant to fund the reactor at the German brewery. We may see a lot more of this if Europeans have sniffed out early news.

MVTG!!!!

[TheFinalCD]

Team "BRING IT" now #7 on Top 10 Active Stock Traders Forums
1. STOCKGOODIES PLAYS OF THE WEEK
2. Sizzling Stock Picks
3. $Pistol Pete$, $Mick$ & Friends Stock Pic
4. Billionaire Boys Club Member Forum (BBCMF)
5. "WallStreet" Surfers
6. Team "BRING IT" http://investorshub.advfn.com/Team-%22BRING-IT%22-25875/
7. .00 stocks with high volume breakout above 50
8. BB's Stock Haven
9. FLEX NATION
10. MOMO'S BREAKOUT BOARD

Ticker Buzz Cloud (24 hours)
Time Interval: 24hr | 12hr | 6hr | 3hr | 1hr
$$$$ ACTL AMRN ARYC BIEL BIG BMSN CGRA COWI DNRG ELTP EPXY FDBL GRNH HJOE ICNB IMO LBRG LVGI MCGI MINE MMHC MVES MYEC NHMD NTEK NWBO PJET PMCB PNG RMHB RMTD RSHN RXMD SFOR SGBY SIPC SNMN SPCL SVTE TBEV TEUFF TFZI TPAC TRTC UBQU UHLN UNGS USA WMIH ZMRK

[mick]

ah maybe/////\\\\\ Kbridge Energy Corp. (BMMCF)

[AugustaFriends]

quick 25% play!! $AUMN .88 break .90 could see a FAST 25% pop !!! see charts http://schrts.co/4Gn9rg

[AugustaFriends]

$NAK .84 now was a $21 stock - ME very happy with $10

[$Pistol Pete$]

[BottomBounce]

NEWS just out!!!! $AMRS Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products http://www.reuters.com/article/idUSASC096G6

[mick]

good evening. lot pps gains , i like.

[mick]

did anyone see AMGT last night, ????? 12 year old won 1 million and goes to vegas.

[BottomBounce]

$AMRS on fire!! Breakout mode

[mick]

good morning, 2/3's sept. gone.

[BottomBounce]

$AMRS wow!

[BottomBounce]

$AMRS can we see .60+ today? Hmmm

[AugustaFriends]

MNGA Volume !!! watch it !! Charts

Note 1: Please alert the board of any stock crossing the 20,50,20dma’s on daily or weekly chart.

(link back for more charts)

Note 2: Please do an 8x34 chart on the stock; the 8x34 cross is the initial reversal sign of most stocks. Use the link below, just replace the ticker symbol. Post on the board when a stock crosses the 8DMA or the 34DMA and when the 8x34 cross is about to occur.

check to see if your stock has 8x34 cross in the making, look at Full Sto, and CMF indicators. just replace the ticker with your TICKER

http://stockcharts.com/h-sc/ui?s=MNGA&p=D&yr=0&mn=3&dy=0&id=p11960084343

[mick]

things are pretty good, got clear test for bladder, graduated to one yr checkup.

[mick]

GOOD MORNING MY FRIEND. 09-25-2016

[BottomBounce]

**Breaking out >>> $AMRS .5101 + 0.0163 (3.30%)

[mick]

good morning.

[mick]

off to laughlin ,nv. tomorrow , be back friday night.

[BottomBounce]

$AMRS Daily and Weekly Charts

[BottomBounce]

$FDBL Social Media Stock... .0042 + 0.0004 (10.53%)

[mick]

good evening, finally home, keno treated me good. 2-11- 12-13-22, others so so.

comps are good.

[BottomBounce]

#SHORTCOVERING @ $AMRS

[mick]

GOOD MORNING MY FRIEND.

[mick]

good morning, 10-20-2016

[mick]

you follow ????? http://www.otcmarkets.com/stock/GCEI/quote
gcei
http://www.otcmarkets.com/stock/GCEI/news
reading

may announce patent news and a deal~
st ALGAE R.E.I.T.
new technology~whether it is also related to the $40M Bond is another thing.

They have a technology for the conversion of slurry pond residues to
dry slurry through its' proprietary "Cyclonic Dredging" technology

They are also working on the construction of specialized
gasification plants using the Company's gasification/pyrolytic
steam reforming technology to convert carbon based feedstock into
clean usable energy.

http://www.otcmarkets.com/stock/GCEI/profile

[BottomBounce]

$VAPE NEWS!!! MMJ

[BottomBounce]

** $INSY MJ play "BigLeague" $GWPH kinda play :)

[BottomBounce]

$KNDI Kandi Technologies Announces it Will Report Third Quarter Financial Results and Hold a Conference Call on November 9, 2016
https://globenewswire.com/news-release/2016/10/28/884285/0/en/Kandi-Technologies-Announces-it-Will-Report-Third-Quarter-Financial-Results-and-Hold-a-Conference-Call-on-November-9-2016.html

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Requests Pre-IND Meeting with FDA for its Pancreatic Cancer Clinical Trial





LAGUNA HILLS, Calif., Nov 01, 2016 (GLOBE NEWSWIRE via COMTEX) --

PharmaCyte Biotech, Inc. (otcqb:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box [(R)] , today announced that it has submitted a request for a pre-IND meeting with the U. S. Food and Drug Administration (FDA) for its planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
PharmaCyte has submitted questions to the FDA as part of a pre-IND meeting request where aspects of the content of the Investigational New Drug (IND) application itself (CMC section, clinical trial description, etc.) will be discussed. After the FDA has responded to the questions and issued comments, PharmaCyte must address them to the FDA's satisfaction. A review of PharmaCyte's responses by the FDA will then take place at the formal pre-IND meeting where final agreement between PharmaCyte and the FDA on all aspects discussed will be reached. With this information, the IND will be submitted by PharmaCyte and reviewed by the FDA. Once the IND is found to be acceptable to the FDA, patients can be enrolled in PharmaCyte's clinical trial.

–– ADVERTISEMENT ––



PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, said of the meeting request, "We are pleased that PharmaCyte has taken the first step towards regulatory approval in the United States of its therapy for LAPC. When I started to lead this company in January 2014, my first goal was to surround our technology with the best of the best in the biotech sector. I believe we have more than accomplished this goal as we have compiled an internationally renowned team that will lead PharmaCyte into what we expect to be a pivotal human clinical trial. My second goal was to get our therapy to the FDA, and with this pre-IND meeting request, we have accomplished this goal as well. My ultimate goal, of course, was and is to get our pancreatic cancer therapy into clinical trials and approved by the FDA. I feel we are well on our way to accomplishing this goal."


PharmaCyte's clinical trial in patients with LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane [(R)] plus gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other group will receive PharmaCyte's pancreatic cancer therapy (encapsulated genetically modified live human cells that can activate the cancer prodrug ifosfamide plus low doses of the prodrug to eliminate side effects from the chemotherapy). In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte's therapy can shrink inoperable tumors so that they become operable.

About PharmaCyte Biotech

PharmaCyte Biotech a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box [(R)] ." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. These encapsulated cells are implanted as close to the patient's cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and results in no side effects.

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box [(R)] technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte's intellectual property and PharmaCyte's continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: [phone] Email: [e-mail]
Copyright (C) 2016 GlobeNewswire, Inc. All rights reserved.

[BottomBounce]

SOLID MJ STOCK $INSY 11.16 +0.472 (4.42%)

[mick]

GOOD MORNING, 11-08-2016

[mick]

11-08-2016 TODAY IS *D* DAY FOR BALLOT VOTE ON MEDICAL RECREATIONAL MARIJUANA, CANNABIS , HEMP

[mick]

To All, GOD BLESS AMERICA AND FOR OUR FREEDOM/ good morning, happy veteran's day 11-11-2016

[mick]

good morning, how are things going ?????

[BottomBounce]

**** $NBGGY National Bank of Greece VOL..<

[BottomBounce]

Greek Stocks this week $DRYS & $NBGGY on LOCK!

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy





http://www.marketwatch.com/story/pharmacyte-biotech-granted-fda-pre-ind-meeting-for-pancreatic-cancer-therapy-2016-11-29-9184110

[mick]

it is dos eyes, good morning, wife doing better last couple days. dec.9, 2016 doc looks to m.r.i. again.

[AugustaFriends]

Target $2.25 !!! $GPL 1.55 === BOOOOOM soon very soon !! @1.54 now

[mick]

WE ARE HONORING WORLD WAR TWO / GERMANY JAPAN, UNITED STATES OF AMERICA,

WE THANK ALL THAT DEFENDED U.S.A.

WE PRAY FOR ALL, HONOR ALL U.S.A VETS, FAMILY AND FRIENDS, CIVILIANS THAT BUILT AMERICA GREAT.

AGAIN 'STOCKGOODIES PLAYS OF THE WEEK '
WE HONOR ALL, FAMILY AND FRIENDS.

DEC.7,1941

P.S.MANY DIED ON FIRING LINE.

[mick]

it those eyes, good morning.

[mick]

good morning MT, things are good, wife is covering after great fall.

the kingsmen are putting her together again.

fell nov. 8 , 2016

fractured pelvis.

doctor said pelvis healed friday.

religious doctor we held hands and prayed for all and family.

wife met an angel in her room at the hospital, roommate has cancer
4th stage. the lady taking good.

[mick]

we may have mede histoory first time offline more than one day. good afternoon.

[BottomBounce]

$ASTI .004 + 0.0011 (37.93%) MACD Bullish Crossover!

[AugustaFriends]

$URRE Must see chart look at the 200MA weekly at $18.90 -- Can we say BOOOM Trump Make America Nuclear Great Again http://schrts.co/SIEnUH

[SIBA420]

SNMN Security Details

Market Value1 $5,006,739 a/o Jan 26, 2017

Share Structure
Authorized Shares 4,000,000,000
Outstanding Shares 3,129,211,734
Float is about 730,000,000

Par Value 0.001

*Now get rid of 2.2 Billion Shares from court case and we look very much like this below stock... HMMMMMMMMMM??? Copper is on the way..

ICN3 Security Details

Market Value1 $21,836,388 a/o Jan 26, 2017

Share Structure
Authorized Shares 2,000,000,000 a/o Jan 05, 2017
Outstanding Shares 814,790,609 a/o Jan 05, 2017
Float 740,786,505 a/o Dec 15, 2016

Par Value 0.001

Just wait for this PR to come out and I And others here know by talking to Troy back in March 2016 his plan to do such.

I can see it now reading something like this......

CEO Troy stated, "One of our intermediate term goals is to up-list to the OTCQB level. One of the requirements to up-list is to trade above a penny for thirty days. Another is the requirement to be fully reporting. We feel strongly that these two objectives are mutually compatible."



And with SNM Global Holdings not far from COCO Cocktail, bet that deal is done and already growing SNMN revs..

https://www.facebook.com/cocococktails

https://www.google.com/maps/dir/26.19482,-80.140165/7950+NW+53rd+St+%23337,+Miami,+FL+33166/@26.0077045,-80.532121,10z/data=!3m1!4b1!4m8!4m7!1m0!1m5!1m1!1s0x88d9bbd3d6e21a4f:0xa7324e9bf6973191!2m2!1d-80.3266588!2d25.8211289?hl=en-US


SNMN .01 Plus coming and with the chart we have it wont take long..

Have a great weekend friends.
HR

[AugustaFriends]

$XRA 1.05 Target 1.50 see chart

[Ecomike]

$MVTG up 30% on 8 million shares of buys, 15% of the float traded today!!!

Get your $MVTG DD here and now at

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129549754

[BottomBounce]

Friendable Inc $FDBL new investor presentation. http://ir.friendable.com/wp-content/uploads/2017/01/FDBL-Investor-Presentation_January_2017.pdf

[AugustaFriends]

*** $ATNM 1.47 weekly ALERT!!!

[AugustaFriends]

$ATNM 1.45 watch for 1.52 Breakout - 8x34dma cross coming - daily MACD cross at 1.52 confirms run

[BottomBounce]

$FDBL 19m shares on the bid!!!!!!! Wowzer!! $FDBL

[mick]

good morning, 04-03-2017

[$Pistol Pete$]

$PMCB UNC-Led Cannabis Research Sees Significant Progress PMCB

Research led by University of Northern Colorado Professor Richard Hyslop is making significant progress in developing a targeted cancer treatment using cannabinoids as a chemotherapy agent, according to a news release issued Monday.

The UNC research has concentrated on the feasibility of developing cells capable of producing an enzyme that can convert inactive cannabis compounds into an active anti-cancer drug.

Hyslop, who's working on the project with PharmaCyte Biotech Inc., summarized the progress during presentations last week at the 253rd American Chemical Society National Meeting & Exposition in San Francisco.

Researchers to date have observed five cell lines that produce desired enzymes to convert inactive cannabis compounds into anti-cancer drugs once they're injected, using PharmaCyte's encapsulation technology, and then activated directly at the site of a tumor.

Hyslop has been involved in cancer research for four decades and is leading a team of scientists from UNC to develop a "green" approach to treating solid tumors, initially brain cancer.

http://www.unco.edu/news/releases.aspx?id=10787

[Abondanceinvest]

GM Manic$, Alert soon..SDVI lot$ of News$ Comingg..Strategic Partnerships
To Solve IOT Challenges
We actively support IOT teams with strategic thinking and access to transformative resources to enable market expansion.

Soon http://www.signaturedevices.com/

Soon 2 New IOS App...
http://www.graffitientertainment.com/

Soon

Truck IT is the new way
to manage your hauling operations
http://www.truckitapp.com/

PIPELINE NEWS$$$$$$$$$$$$ is coming pennyland too my

[mick]

good morning, T.G.I.F. 04-21-2017

[mick]

good morning, watching gold, blackhawks died

[Abondanceinvest]

Gm Manic$ Nice chart$ SDVI 5-10 bagger coming
http://investorshub.advfn.com/uimage/uploads/2017/4/25/mqxefsdvi_4-25-17_chart.png

News Soon tic-tac

[mick]

good morning, car repair been keeping me busy.

[AugustaFriends]

$HUSA up 21% running

[Ecomike]

$MVTG Just another day in Mantraville (MVTG)
Did you nibble at em yet???
2.5 mil shares bought at the ask as it ran today!!!! That is 10 times the volume 2 days ago.

[mick]

HAVE''EM EYES, good morning

[Ecomike]

The $MVTG party continues for good reason, fresh party invites have been mailed out!!! :-)

[mick]

good morning, casino wkend. good comps. may day, 05-01-2017

[AugustaFriends]

$BASI watch for HUGE 1.61 BREAK target is $2.42

[mick]

good morning, 05-04-2017

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Updates IND Submission Process in Interview with Facet Life Sciences PMCB



May 08, 2017 09:00 ET | Source: PharmaCyte Biotech, Inc.
LAGUNA HILLS, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released an educational, interview-style Q&A article with Sarah DeMare, the Product Development Champion with Facet Life Sciences and U.S. Agent for PharmaCyte, who discusses the IND submission process for PharmaCyte’s upcoming clinical trial in locally advanced pancreatic cancer (LAPC).

Since coming to an understanding with the FDA on a path forward after PharmaCyte’s pre-IND meeting in January, is there a list of items that you can share with us that when completed will allow PharmaCyte to file its Investigational New Drug application (IND)?

Sarah DeMare: “The single most important item PharmaCyte needed to learn from the FDA at the pre-IND meeting was the acceptability of PharmaCyte’s proposed cell line. Without that understanding, PharmaCyte was unable to move forward with the manufacture of its product candidate for the LAPC clinical trial.”

“An IND encompasses many things, dealing with the manufacture and characterization of the product candidate, the clinical study design and nonclinical studies. PharmaCyte’s therapy for pancreas cancer has undergone or been part of several studies, so incorporation of that information into the IND is not ‘rate limiting’ or ‘slowing down the progress towards submitting an IND.’ The clinical study design that PharmaCyte agreed to undertake after meeting with the FDA is currently being drafted. This is also not rate limiting. To conduct the clinical trial, PharmaCyte will need to manufacture, test and release a Master Cell Bank, a Working Cell Bank and the encapsulated live cells. This information is also required to be described and documented in detail in the IND. The manufacture of these items is the rate limiting factor involved in submitting the IND.”

“Before the IND is filed, the following items must be available for inclusion:

(a) Documentation of preclinical work done on the cells.
(b) Toxicology studies.
(c) Documentation of preclinical work done on the capsules themselves.
(d) A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.
(e) Labeling for the final investigational biologic product.
(f) Previous evidence of human experience with the pancreas cancer therapy (low-dose ifosfamide plus Cell-in-a-Box® encapsulated genetically modified human cells).
(h) The Investigator’s Brochure.
(i) The Informed Consent Form
(j) The Case Report Form”

Can you talk about the items on the list in relation to PharmaCyte’s progress and what further rate limiting steps are on the path to filing the IND?

Sarah DeMare: “Documentation of work done on items (a), (b) and (c) and a significant amount of material concerning item (d) have been accumulated to date. As for item (f), publications of Phase 1/2 and Phase 2 trials that were published in scientific journals are “in-house,” as are original clinical reports of those clinical trials. The clinical trial protocol is nearing the “final” stage. Items (h), (i) and (j) will be written by Translational Drug Development (TD2), the Contract Research Organization (CRO) PharmaCyte has retained to conduct the clinical trial in the U.S. and oversee its conduct in Europe by Clinical Network Services (CNS).”

“The rate limiting step to being able to file the IND and, ultimately, begin the clinical trial is the manufacture of the combination drug product. For live cell-based products, a Master Cell Bank or ‘MCB’ first needs to be manufactured, characterized, tested and released. The speed at which the MCB can be produced is dependent on several different things. First, is the availability of starting materials. Some starting materials can have a significant lead-time when ordering, and you cannot begin manufacture until you have all your starting materials. Second, is the growth rate of the live cells. Cells grow at different rates. There isn’t much that can be done to speed up that process. Unfortunately, it is not a 1 to 2-day event. “

“Also, when working with a Contract Manufacturer Organization (CMO) to make your cell bank, some things are out of your control. For example, scheduling. CMOs typically schedule their manufacturing rooms out months in advance for their clients, so sometimes you need to wait in the queue for your turn. In addition, and perhaps most importantly, the MCB needs to be tested to ensure its quality, which is of utmost importance. These tests are also not tests that can always be done quickly. Sterility is a good example. This test is mandatory to ensure the sterility of your MCB and takes approximately 6 weeks to obtain results.”

“The purpose of creating a MCB is to provide a repository of live cells that are essentially identical to the material tested in clinical trials and throughout the development process. After creating a MCB, a Working Cell Bank or ‘WCB’ must be manufactured. Creation of a WCB is an important step, as it allows your Master Cell Bank to have a longer useful life.”

“This is an important point, and it’s worth illustrating. Let’s say you can make 300 vials in your MCB. Let’s also say that each vial of cells can produce enough drug product to treat 100 patients. That would mean you could potentially treat 30,000 patients with the entire MCB. Sounds like a lot, right? Maybe, but this MCB will need to provide cells to patients for years to come. At some point in the future, the MCB will be depleted. This would require another MCB to be produced, and in such a complex system there would be no guarantee that the original cells could be duplicated exactly. In the best case, this means extensive testing would be needed to prove that the new MCB is equivalent to the old MCB.”

“If those tests reveal differences that could affect efficacy, a new clinical study may be needed to demonstrate that the new MCB is equivalent to the old MCB. There is always the potential that it will not be equivalent. That is the situation the FDA would like to avoid, which is why a Working Cell Bank is needed. To make a WCB, you take one vial of your Master Cell Bank and grow it into more vials to become your Working Cell Bank. So, theoretically, you could get 200 vials of your Working Cell Bank from 1 vial of your Master Cell Bank. Assuming one vial of your WCB still treats 100 patients, you could treat 20,000 patients from only 1 vial of Master Cell Bank. Using this example, a 200-vial Master Cell Bank could treat up to 4 million patients. Compare that to the 30,000 patients you could treat with the entire Master Cell Bank, and you can see that having a WCB allows your MCB to go much further and last much longer.”

“Producing a Working Cell Bank is similar to the Master Cell Bank in that it takes time for the live cells to grow, and you need to test and release the live cells. Sterility testing is still required, and it still takes 6 weeks to perform.”

“Finally, with the Working Cell Bank ready, the drug product can be manufactured, tested and released. The FDA will want to see the test results that demonstrate the quality of the drug product in the IND. So, the IND cannot be filed until the testing of the drug product is completed.”

In your experience with the FDA, discuss the importance of following the FDA's guidance to the letter?

Sarah DeMare: “The FDA is most concerned with patient safety. So, while there may be opportunity to state that certain pieces of information will be available at a later date, those issues that directly impact patient safety are important to include in your IND. From a manufacturing perspective, for a product that is being injected into the body, sterility is of utmost importance to the FDA. Not only sterility of the live cells in the vials, but understanding the manufacturing process, the environment in which the cells were manufactured and where the starting materials came from are critically important. There is a lot of information about this to be described in detail in the IND.”

“Following the guidance that the FDA has provided at the pre-IND meeting gives the company the best chance of success at having the IND accepted after the 30-day period.”

What are the potential downsides to submitting an IND that doesn't follow the FDA's guidance to the letter?

Sarah DeMare: “The obvious answer is that if the FDA feels like there are concerns with patient safety, the FDA will place PharmaCyte on clinical hold until those concerns can be resolved. Depending on what the issues are, they may be resolved with some additional testing or characterization, perhaps describing something with a bit more clarity or providing site processes and procedures. The worst-case scenario would be if the FDA found an issue with the Master Cell Bank that could not be resolved and resulted in needing to manufacture the Master Cell Bank, Working Cell Bank and drug product again to the FDA’s satisfaction. This is why it is so important to make sure it is done right the first time.”

“Another less obvious answer is the impression it would leave on the FDA. A sponsor of an IND, like PharmaCyte, is going to have many opportunities to interact with the FDA on its path to a Biologics License Application (BLA) approval. An initial IND is that ‘first impression’ so to speak. Having a well thought out, well put together and well written IND with all of the required information can demonstrate to the FDA that the sponsor understands what needs to be done and is serious about the intent to bring an important and novel therapy to patients.”

If PharmaCyte, or any company for that matter, follows the FDA's guidance step by step on the path to filing an IND and the final submission is closely married to that which was discussed in the pre-IND meeting, is it your experience that the company can get through the 30-day period without comment from the FDA?

Sarah DeMare: “In my personal experience, there are always comments from the FDA during the 30-day wait. However, under the scenario you have described, the comments should be minor and the sponsor should be able to quickly respond to them without issue. For example, the FDA may ask for slight changes in wording to the protocol. However, those issues will be communicated and will need to be responded to within 30 days. The issues that arise during the 30-day window are almost always related to patient safety. It is very common for the FDA to send the ‘safe to proceed’ letter to the sponsor with a list of items for the sponsor to consider or complete over the course of development, but that doesn’t impede the sponsor from beginning its clinical trial.”

PharmaCyte will follow up this interview-style Q&A article with an additional interview with TD2 that will be more focused on the clinical trial, clinical sites, training, etc. and will discuss what work is being done in parallel with the work that is ongoing to complete the IND discussed by Ms. DeMare. It is this clinical-focused work that will allow PharmaCyte to begin its clinical trial almost immediately upon receiving the “safe to proceed” letter from the FDA—30 days after filing the company’s IND.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

In addition to developing a novel therapy for cancer, PharmaCyte is developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Contact:

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]


https://globenewswire.com/news-release/2017/05/08/980144/0/en/PharmaCyte-Biotech-Updates-IND-Submission-Process-in-Interview-with-Facet-Life-Sciences.html

[mick]

good morning eight [8], took wkend off to do some gaming, 05-08-2017

[AugustaFriends]

$CERC break weekly 20MA (.77) Target is $1.15 to $2.30 AREA =BOOOM

[AugustaFriends]

$CERC .75!!! .77 BREAK will be huge!!

[AugustaFriends]

$AAU watch for 1.38 BREAKOUT bouncing off daily and weekly Supports http://schrts.co/QaB54j

[$Pistol Pete$]

$PMCB bounce big time today

[Ecomike]

$MVTG continues to rally unnoticed, in a stealth rally that is worthy of notice!

Break out past .03 shows a target of .30 / share next

Major news is pending, so she might ran like she did in 2014 from .0068 back to .75

OS 144 Mil, float under 70 Mil, CEO owns 13 mil founder shares he held at $1.25 and later at .75 and never sold. IPO was in 2008. 7 Issued patents now in 6 countries, GE is their new partner with huge Canadian pilot plant funding pending. Plant to make diesel fuel out of waste CO2 power plant exhaust using solar power.

$MVTG also just bought a Civil engineering design build firm that specializes in Cell towers (they need back up power which MVTG's new ERC-MRFC fuel cell energy storage technology could supply in the future. Will AWS, which they just bought do this next?). The company $MVTG just bought has 10 Million a year in revenue and is profitable. That is a huge change for MVTG who had just 7 issued patents and lived off government grants and a million dollar deal with GE-Alstom from 2014. Do some DD folks, you will like what you find.

[mick]

good morning my friend, goods to ya and all this morning. no may day for this month of may 2017

[mick]

IT IS DA EYES, GOOD MORNING. 05-26-2017

[mick]

good morning my friend, long wkend, 05-27-2017

[mick]

good morning, 06-04-2017

[mick]

good morning, guns and roses

[mick]

it is in da eyes/ good morning my friend/ 06-07-2017

[mick]

good afternoon my friend.

[mick]

same to you my friend/ 06-11-2017

[mick]

IT IS FLAG DAY, WE SALUTE. JUNE 14,2017 --- 100 YRS OF ARMY SERVICE FROM WORLD WAR ONE TIL THIS MIDDLE EAST WAR.

WE THANK ALL OUR VETERAN'S AND WE PRAY FOR ALL FAMILY'S AND THEIR DEPARTED.

[mick]

good morning my friend/ israel in cahoots wit europe for pipelline

[mick]

good morning my friend/ happy father's day

[mick]

did some coin hopping/came across maybe rare one 1984 half dollar.

above
IN GOD WE TRUST/ 1960 STAMPED/

OVER THE DATE 1984/ 1985 STAMPED ABOVE DATE/

GOLD TONED

I STILL CAN'T GET BOX OF LARGE DOLLAR'S

[mick]

roger stone is going to white house to ask trump/attorney general to relax the marijuana law

give the law to the states,

[mick]

good morning, 06-21-2017

[mick]

$GILD MAJOR BREAKOUT.

[mick]

i had to go to tucson V.A. for heart stuff.

[mick]

good morning, 07-01-2017

[$Pistol Pete$]

$EQLB EQ Labs Inc. Begins Strategic Partnership with AirGo Food & Beverage

Read more: http://m.digitaljournal.com/pr/3403728#ixzz4m6OAHUh1

[AugustaFriends]

$DXTR just added 30,000 shares target .50 cents on these shares

[AugustaFriends]

$PLG weekly PSAR buy signal ; possible return to 34ma weekly or $1.20's http://schrts.co/DZh2x8

[AugustaFriends]

$AUMN .611 BREAK will be huge watch it breaking 200dma

[LEFTY1182]

UAMM .01 sleeper MJ DEBT FREE LOW FLOAT MONSTER ABOUT TO BE UNLEASHED!

[Ecomike]

$MVTG 's time to shine, 10-Q just out, 3 million in sales-revenue in 3 months, so what we were told was more than true about MVTG buying AWS!!! Stock just went from locked float dead volume for a month to 1 million shares traded up 43% in 2 hours, and #3 on the break out board!!!

64 mil float, AS 275 Mil and used up, insiders own 51%!!!

about $800,000 in gross margin profit on the sales!!!

This one is going to soar again.
Link to the 10-Q
https://ih.advfn.com/p.php?pid=nmona&article=75901753

[Ecomike]

$MVTG strong rally today up 25% on 10-Q earnings and huge revenue jump to 3 million $ in 3 months. Up from zero last year!!!

Locked float 64 mil shares!!!!

[Ecomike]

$MVTG just reported going from zero revenue sales (before they bought AWS) to 3 million in sales/revenue in the last 3 months!!!

They may see a 10 fold increase in sales as they repair, and install and maintain Cell phone towers in Puerto Rico and Florida, and the USA. The stock is at 10 year low, market cap under 1 million right now, crazy low!!!

$MVTG is back!!!! Last rally was 1200%, before that it ran .0068 to .75 in 2014!!!! Now they have massive revenue!!!

[AugustaFriends]

Good Morning SG's

AF's top 5 as of today $CERC 1.13 $GST .82 $XCO 1.34 $AXU 1.23 $ARLZ 1.44

[BottomBounce]

$GEVO BREAKING OUT $1+ coming

[AugustaFriends]

$GSS .84 Just Bought 25K shares Target $1.10 http://schrts.co/izxosw